BioMedNewsBreaks – Revive Therapeutics Ltd. (CSE: RVV) (OTC: RVVTF) to Evaluate Psilocybin in Methamphetamine Use Disorder Treatment Clinical Trial

Revive Therapeutics (CSE: RVV) OTC: RVVTF), a specialty life-sciences company focused on the research and development of therapeutics for medical needs and rare disorders, has finalized a clinical trial agreement with the Board of Regents of the University of Wisconsin System (“UWS”). The agreement calls for Revive Therapeutics to conduct a clinical study entitled “Phase I Study of the Safety and Feasibility of Psilocybin in Adults with Methamphetamine Use Disorder.” The agreement calls for Revive Therapeutics to have an option to obtain an exclusive, worldwide, royalty-bearing commercialization license to all rights, title and interest that UWS may obtain in any invention resulting from the clinical study. “We are delighted to be collaborating with clinical researchers at the University of Wisconsin‒Madison to advance development of psilocybin for the potential treatment of methamphetamine use disorder,” Revive’s CEO Michael Frank in the press release. “We are building a pipeline of clinical-stage psychedelic-derived therapies for addiction disorders with a focus on psilocybin with unique dosage forms.”

To view the full press release, visit http://ibn.fm/aMSs4

About Revive Therapeutics Ltd.

Revive is a life-sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders. The company is prioritizing drug-development efforts to take advantage of several regulatory incentives awarded by the Food and Drug Administration (“FDA”) such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of cannabidiol (“CBD”) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit www.ReviveThera.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork